Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations

MeSH terms

• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Carboplatin / administration & dosage
• Carcinoma / drug therapy*
• Carcinoma / genetics*
• DNA Mutational Analysis
• Drug Resistance, Neoplasm
• ErbB Receptors / genetics*
• ErbB Receptors / physiology
• Female
• Gefitinib
• Humans
• Ovarian Neoplasms / drug therapy*
• Ovarian Neoplasms / genetics*
• Paclitaxel / administration & dosage
• Quinazolines / administration & dosage
• Treatment Outcome